#USA #New York #class action lawsuit #Pomerantz Law Firm #Aldeyra Therapeutics

Pomerantz Law Firm Issues Investor Alert on Aldeyra Therapeutics Class Action Lawsuit

Pomerantz LLP, a prominent law firm known for its expertise in securities litigation, has formally announced that a class action lawsuit is now in effect against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). This action is particularly crucial for investors who have suffered financial losses resulting from their investments in Aldeyra. The firm is urging these individuals to come forward and explore their options regarding this lawsuit.

Background of the Lawsuit

The lawsuit centers around allegations that Aldeyra and its executive team may have engaged in securities fraud or other questionable business practices. The actions in question allegedly led to a misleading representation of the company’s financial health and the efficacy of its products. The critical details of the lawsuit highlight concerns over the company’s recent communications and disclosures surrounding its investigational drug, reproxalap.

On March 17, 2026, Aldeyra publicized that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application for reproxalap, intended for treating dry eye disease. The FDA’s letter criticized Aldeyra for not providing substantial evidence to validate the drug's purported efficacy under the claimed conditions. The unexpectedness of this development triggered a considerable downside in Aldeyra’s stock price, which plummeted by nearly 71%, closing at just $1.24 per share on the same day.

Importance of Swift Action

Affected investors are advised to act promptly. Specifically, they have until May 29, 2026, to file for an appointment as Lead Plaintiff for the class action. Danielle Peyton from Pomerantz LLP is the primary contact for those wishing to get involved, offering assistance in navigating the lawsuit and addressing any queries related to the legal proceedings.

Those interested in participation are encouraged to contact her via email or phone, with the recommendation to provide their contact details along with the number of shares they had purchased in Aldeyra. This step is vital for successfully engaging with the class action process, as it enables the firm to compile a comprehensive list of aggrieved investors.

Conclusion

The case symbolizes an ongoing commitment by Pomerantz LLP to protect investors' rights, reflecting their track record of fighting against corporate misconduct and securing favorable resolutions for class members. Having successfully advocated for numerous cases in the realm of securities fraud, the firm is now turning its focus to Aldeyra in hopes of achieving justice for those impacted by the company’s alleged failures. Investors are encouraged to stay informed and participate in this potential legal action to uphold their rights and seek reparations for any financial harms experienced as a result of Aldeyra's actions.

For more information or to view a copy of the legal complaint, interested parties can visit Pomerantz Law Firm's official website.